目的 探讨英夫利西单抗(IFX)治疗儿童克罗恩病(CD)的临床疗效与安全性。方法 2011年1 月至2014 年12 月确诊为CD 的患儿13 例,在常规综合治疗基础上,加用IFX(5 mg/kg)治疗,回顾性分析所有患儿治疗前及治疗30 周后的临床表现、实验室指标及儿童克罗恩病活动指数(PCDAI)的变化,同时内镜下进行疗效评估。结果 所有患儿腹痛、腹泻、便血等临床症状在治疗后短期内迅速缓解并未见复发,治疗30 周后白细胞计数、红细胞沉降率、C 反应蛋白及PCDAI 较治疗前明显降低,血红蛋白较治疗前明显升高(P<0.05);2 例患儿复查内镜,1 例痊愈,1 例无效;所有患儿均未见药物不良反应发生。结论 IFX 治疗儿童CD 临床疗效显著,无明显的不良反应,可作为治疗儿童CD 的首选方案之一。
Abstract
Objective To evaluate the efficacy and safety of infliximab in the treatment of Crohn's disease in children. Methods Thirteen children who were diagnosed with Crohn's disease and received routine comprehensive treatment and infliximab (5 mg/kg) between January 2011 and December 2014 were enrolled. The changes in their clinical manifestations, laboratory indices, and Pediatric Crohn's Disease Activity Index (PCDAI) after the 30-week treatment were analyzed retrospectively. Meanwhile, endoscopy was performed to evaluate therapeutic effects. Results The symptoms such as abdominal pain, diarrhea, and bloody stool were relieved soon after infliximab treatment, with no recurrence observed;after the 30-week treatment, the white blood cell count, erythrocyte sedimentation rate, C-reactive protein, and the PCDAI decreased, while the hemoglobin increased significantly compared with those before treatment (P<0.05). After infliximab treatment, two children underwent endoscopy. The endoscopy showed that one child was cured, and the other child failed to respond to the treatment. No adverse drug reactions were seen in all patients. Conclusions Infliximab treatment has significant clinical effects in children with Crohn's disease, with no obvious adverse reactions, and therefore, it can be applied as one of the preferred alternatives for treatment of Crohn's disease in children.
关键词
克罗恩病 /
英夫利西单抗 /
治疗 /
儿童
Key words
Crohn's disease /
Infliximab /
Treatment /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 胡品津. 炎症性肠病诊断与治疗的共识意见(2012 年·广州) 解读[J]. 胃肠病学, 2012, 14(15):709-711.
[2] Buderus S, Scholz D, Behrens R, et al. Inflammatory bowel disease in pediatric patients:Characteristics of newly diagnosed patients from the CEDATA-GPGE Registry[J]. Dtsch Arztebl Int, 2015, 112(8):121-127.
[3] Randall C, Vizuete J, Wendorf G, et al. Current and emerging strategies in the management of Crohn's disease[J]. Best Pract Res Clin Gastroenterol, 2012, 26(5):601-610.
[4] 孙怡燕, 吴永发, 徐灿, 等. 英夫利西单抗治疗克罗恩病的疗效观察[J]. 第二军医大学学报, 2010, 31(3):338-339.
[5] 邓应江, 敖智容, 秦红, 等. 英夫利西单抗治疗克罗恩病的疗效与安全性研究[J]. 西南国防医药, 2012, 22(5):505-507.
[6] 陈志勇, 游洁玉, 刘莉, 等. 英夫利西单抗治疗儿童克罗恩病疗效观察[J]. 继续医学教育, 2014, 28(5):23-25.
[7] 中华医学会儿科学会消化学组儿童炎症性肠病协作组. 儿童炎症性肠病诊断规范共识意见[J]. 中国实用儿科杂志, 2010, 25(4):263-265.
[8] Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease:the ACCENT I randomised trial[J]. LANCET, 2002, 359(9317):1541-1549.
[9] Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease:a prospective multicentre study. Groupe d'Etudes Theraeutiques des Affections Inflammatoires du Tube Digestif (GETAID)[J]. Gut, 1989, 30(7):983-989.
[10] Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases[J]. Gastroenterology, 2011, 140(6):1756-1767.
[11] even G, Assaad A, Biehl T, et al. Use of anti tumor necrosis factor-alpha monoclonal antibody for ulcerative jejunoileitis[J]. World J Gastroenterol, 2012, 18(36):5135-5137.
[12] Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review[J]. Gastroenterology, 2012, 142(1):46-54.
[13] Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease:top-down or step-up?[J]. Dig Dis, 2007, 25(3):260-266.
[14] Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn's disease[J]. Clin Gastroenterol Hepatol, 2015, 13(7):1293-1301.
[15] Poullenot F, Laharie D. First line therapy of inflammatory bowel disease[J]. Rev Prat, 2014, 64(9):1242-1248.
[16] Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases:a huge review[J]. Minerva Gastroenterol Dietol, 2010, 56(2):233-243.
[17] Fernandes C, Allocca M, Danese S, et al. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease[J]. Immunotherapy, 2015, 7(2):175-190.
[18] Vatansever A, Çekiç C, Ekinci N, et al. Effects of mucosal TNFalpha levels on treatment response in Crohn's disease patients receiving anti-TNF treatment[J]. Hepatogastroenterology, 2014, 61(136):2277-2282.
[19] 陈洁. 炎症性肠病[M]//陈洁, 许春娣, 黄志华. 儿童胃肠肝胆胰疾病. 北京:中国医药科技出版社, 2006:213-222.
[20] Moss AC, Fernandez Becker N, Jo Kim K, et al. The impact of infliximab infusion reactions on long-term outcomes inpatients with Crohn's disease[J]. Aliment Pharmacol Ther, 2008, 28(2):221-227.
[21] Han PD, Cohen RD. Managing immunogenic responses to Infliximab:treatment implications for patients with Crohn's disease[J]. Drugs, 2004, 64(16):1767-1777.
[22] Lis K, Kuzawińska O, Bałkowiec-Iskra E. Tumor necrosis factor inhibitors-state of knowledge[J]. Arch Med Sci, 2014, 22, 10(6):1175-1185.
[23] Uyanikoglu A, Ermis F, Akyuz F, et al. Infliximab in inflammatory bowel disease:attention to adverse events[J]. Eur Rev Med Pharmacol Sci, 2014, 18(16):2337-2342.
[24] O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease:a systematic review and meta-analysis[J]. Inflamm Bowel Dis, 2014, 20(1):1-6.
基金
国家自然科学基金青年基金(81400585);辽宁省科委基金资助项目(2014021042)。
PDF(1598 KB)
